OTCMKTS:ABSCF AB Science (ABSCF) Stock Price, News & Analysis $1.60 0.00 (0.00%) As of 05/27/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About AB Science Stock (OTCMKTS:ABSCF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AB Science alerts:Sign Up Key Stats Today's Range$1.60▼$1.6050-Day Range$1.57▼$1.6052-Week Range$0.80▼$1.60VolumeN/AAverage Volume640 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.Read More… Receive ABSCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter. Email Address ABSCF Stock News HeadlinesAB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025 | uk.finance.yahoo.comAB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinibMay 16, 2025 | uk.finance.yahoo.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 28, 2025 | Porter & Company (Ad)AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingMay 6, 2025 | finance.yahoo.comAB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemiaApril 23, 2025 | uk.finance.yahoo.comAB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseApril 14, 2025 | markets.businessinsider.comAB Science today provides an update on its masitinib platformJanuary 30, 2025 | markets.businessinsider.comAB Science SA (ABP.XD)January 25, 2025 | finance.yahoo.comSee More Headlines ABSCF Stock Analysis - Frequently Asked Questions How have ABSCF shares performed this year? AB Science's stock was trading at $0.90 at the start of the year. Since then, ABSCF stock has increased by 77.8% and is now trading at $1.60. View the best growth stocks for 2025 here. How do I buy shares of AB Science? Shares of ABSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:ABSCF CIKN/A Webwww.ab-science.com Phone(314) 720-0014FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:ABSCF) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump’s Bitcoin Reserve is No Accident…For the first time in history, we have a president who understands crypto's potential to bypass the banking sy...Crypto 101 Media | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AB Science S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share AB Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.